社会民生
参议员们想告诉缉毒警察该如何行医
中文译文
八名参议员希望美国缉毒局重新启用其曾提出但未实施的限制措施,并禁止一种该局早已禁止的毒品。他们在信中敦促该机构撤销其仅提出过的修改方案。
“克拉托姆属于阿片类物质,”这些参议员写道。克拉托姆中的某些成分能与吗啡激活相同的受体。但这并不意味着所有克拉托姆产品都相同。克拉托姆叶中含有微量的7-羟基米特拉吉宁(7-OH),但一杯克拉托姆茶与一片含有高浓度7-OH的药片所含的该成分量可能相差很大。这些参议员的说明忽略了这一在政府决定禁止何种物质时至关重要的差异。由出版《Reason》杂志的非营利组织Reason Foundation发布的一篇新综述介绍了人们长期以来如何使用克拉托姆来缓解疼痛及减轻阿片类药物戒断症状。在一项调查中,使用者表示他们使用克拉托姆是为了缓解焦虑、在避免使用传统阿片类药物时缓解疼痛,或是为了减少或停止使用其他阿片类药物。在致美国卫生与公众服务部的一封信中,九名退伍军人称他们使用高浓度7-OH来缓解疼痛和创伤后应激障碍的症状,并以此替代其他阿片类药物或酒精。这些案例让我们了解了人们为何寻求这类产品。不过,这些产品是否真的能帮助他们,仍需研究人员进一步探究。7月,美国缉毒局提议将7-OH列入第一类管制物质,这一联邦分类通常规定,如果某种化合物在产品中的重量占比超过0.05%,则持有该化合物即构成犯罪。但该提议并未生效。8月,该机构发布命令,将另一种相关化合物——伪吲哚基米特拉吉宁(MP)列入第一类管制物质,不论其浓度如何。
10月14日,美国缉毒局提出了新的限制标准。根据该提议,对于含有重量占比超过0.1%的7-OH或MP的固体产品,将适用第一类管制规定;如果产品同时含有这两种化合物,则将两者浓度相加后进行计算。该提议还为液体设定了单独的浓度限制。此外,还要求每单位重量的7-OH和MP混合物中,必须含有至少100单位的米特拉吉宁,后者是天然克拉托姆中的主要活性成分。即使某种产品的浓度低于上述标准,但如果未能通过第二项测试,仍可能被纳入第一类管制范围。美国缉毒局表示将在11月13日或之后发布相关命令。这是该机构能够发布命令的最早日期。这些限制并未在那一天自动生效,而10月的通知仍维持着8月对MP的规定。截至11月19日,美国缉毒局仍未发布使新限制生效的命令。
在11月16日写给美国缉毒局及食品药品监督管理局的信中,爱荷华州共和党参议员查尔斯·格拉斯利及另外七名参议员称,美国缉毒局将此前允许的7-OH浓度提高了一倍,并将MP从第一类管制物质中移除。这些参议员对固体物质的计算是正确的:0.1%确实是0.05%的两倍。但7月和10月的数值都来自相关提案。而10月的提案则规定,在超过任一阈值的产品中,MP仍需受第一类管制物质的限制。要求食品药品监督管理局解释为何卫生官员建议设定更高的标准是合理的,但要求美国缉毒局恢复其尚未取消的禁令则另当别论。浓度限制实际上对一个人所摄入的剂量信息透露得非常有限。两片大小不同的药片可能含有相同量的7-OH,即便其中一片的浓度超过了限制值,而另一片则低于该限制值。美国缉毒局也承认,目前尚无针对浓缩型7-OH的安全摄入限值的相关研究结果。有哪些证据能够表明参议员们所建议的限值标准能保障消费者的安全?又有哪些证据可以作为起诉那些持有超过该限值产品的成年人的依据?联邦法律将附表一指定用于那些被认为“有很高的滥用可能性”且“在美国目前没有公认的医疗用途”的物质,同时还考虑其他相关标准。国会还赋予美国缉毒局在发现对公共安全存在迫在眉睫的威胁时,暂时将某些物质列入该附表的权力。此次是卫生官员提出了相应的阈值,由美国缉毒局决定是否实施这些标准。目前,联邦缉毒警察已经负责决定成年人可以服用何种药物来缓解疼痛或应对戒断症状。现在有八名参议员想要为他们甚至到小数点后几位都做出决定。药效与成瘾性问题值得重视。成年人应当清楚自己购买的是什么产品,其中每种成分的含量是多少,以及会面临哪些风险。准确的标签、独立的检测以及打击欺诈行为的措施能够有所帮助。禁令可能会改变人们的购买地点和购买物品。那些因疼痛或戒断症状而使用7-OH药物的人可能会转向非法卖家,或转而使用风险更高的药物。参议员们也应要求相关机构对这些风险作出说明。
参议员们要求FDA和DEA在11月30日前给出答复。如果他们所依赖的产品消失,那些正在忍受疼痛或试图戒除其他阿片类药物的人该怎么办?让缉毒机构从事医疗工作已经够糟糕的了,我们真的希望由八位参议员来开处方吗?
原文
Eight senators want the Drug Enforcement Administration (DEA) to revive a limit it proposed but never imposed and ban a drug it already bans. Their letter urges the agency to undo changes it has only proposed.
"Kratom is an opioid," the senators begin. Some compounds in kratom activate the same receptor as morphine. But that doesn't mean all kratom products are alike. Kratom leaves contain trace amounts of 7-hydroxymitragynine (7-OH), but a cup of kratom tea and a tablet containing concentrated 7-OH can deliver very different amounts of the compound. The senators' label glosses over a difference that matters when the government decides what to ban.
A new review from Reason Foundation, the nonprofit that publishes Reason, describes how people have long used kratom to manage pain and ease opioid withdrawal. In a survey, users reported taking kratom for anxiety, for pain while trying to avoid conventional opioids, or to cut back on or stop taking other opioids. In a letter to the Department of Health and Human Services, nine military veterans described using concentrated 7-OH to manage pain and symptoms of post-traumatic stress disorder and to move away from other opioids or alcohol. These accounts tell us why people seek out these products. Whether the products reliably help them remains a question for researchers.
In July, the DEA proposed putting 7-OH in Schedule I, a federal classification that generally makes possession a crime, if the compound makes up more than 0.05 percent of a product by weight. That proposal never took effect. In August, the agency issued an order putting a related compound, mitragynine pseudoindoxyl (MP), in Schedule I regardless of its concentration.
On October 14, the DEA proposed new limits. Under the proposal, Schedule I controls would apply to solid products containing more than 0.1 percent 7-OH or MP by weight, counting both together if a product contains both. The proposal sets a separate concentration limit for liquids. It also requires at least 100 parts mitragynine, the main active compound in natural kratom, for every part of 7-OH and MP combined. A product could fall below the concentration limit and still trigger Schedule I controls if it failed that second test.
The DEA said it would publish an order on or after November 13. That was the earliest date the agency could publish the order. The limits did not take effect automatically on that date, and the October notice left the August order on MP in place. As of November 19, the DEA had yet to publish an order putting the new limits into effect.
In their November 16 letter to the DEA and the Food and Drug Administration (FDA), Sen. Charles Grassley (R–Iowa) and seven colleagues said the DEA had doubled the previously allowable concentration of 7-OH and removed MP from Schedule I. The senators got the arithmetic right for solids: 0.1 percent is twice 0.05 percent. But the July and October figures both came from proposals. And the October proposal would keep MP under Schedule I controls in products that exceed either threshold. Asking the FDA to explain why health officials recommended a higher cutoff is reasonable. Demanding that the DEA restore a ban it hasn't lifted is something else.
A concentration limit tells us surprisingly little about the dose someone takes. Two tablets of different sizes can contain the same amount of 7-OH, even if one crosses the concentration limit and the other falls below it. The DEA acknowledges that controlled human trials have yet to establish safe consumption limits for concentrated 7-OH. What evidence shows that the senators' preferred cutoff would make consumers safer? What evidence would justify prosecuting adults for possessing a product that crosses it?
Federal law reserves Schedule I for substances deemed to have a "high potential for abuse" and "no currently accepted medical use in treatment in the United States," among other criteria. Congress also gave the DEA power to place substances there temporarily when the agency finds an imminent hazard to public safety. Health officials supplied the proposed thresholds in this case. The DEA decides whether to impose them. Federal drug police already decide what adults can take to manage pain or cope with withdrawal. Now eight senators want to make that decision for them, down to the decimal point.
Potency and dependence deserve attention. Adults should know what they're buying, how much of each compound a product contains, and what risks they face. Accurate labels, independent testing, and enforcement against fraud can help. A ban can change where people shop and what they buy. Some people who use 7-OH for pain or withdrawal may turn to illicit sellers or switch to riskier drugs. The senators should ask the agencies to account for those risks, too.
The senators want answers from the FDA and the DEA by November 30. What do they expect people living with pain or trying to get off other opioids to do if the products they rely on disappear? It's bad enough that we let the drug police practice medicine. Do we really want eight senators writing the prescription?
